These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 21698535)

  • 1. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
    Berger A; Schüle S; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAT--the new committee for advanced therapies at the European Medicines Agency.
    Celis P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The advanced therapy classification procedure. Overview of experience gained so far.
    Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges with advanced therapy medicinal products and how to meet them.
    ; ; Schneider CK; Salmikangas P; Jilma B; Flamion B; Todorova LR; Paphitou A; Haunerova I; Maimets T; Trouvin JH; Flory E; Tsiftsoglou A; Sarkadi B; Gudmundsson K; O'Donovan M; Migliaccio G; Ancāns J; Maciulaitis R; Robert JL; Samuel A; Ovelgönne JH; Hystad M; Fal AM; Lima BS; Moraru AS; Turcáni P; Zorec R; Ruiz S; Akerblom L; Narayanan G; Kent A; Bignami F; Dickson JG; Niederwieser D; Figuerola-Santos MA; Reischl IG; Beuneu C; Georgiev R; Vassiliou M; Pychova A; Clausen M; Methuen T; Lucas S; Schüssler-Lenz M; Kokkas V; Buzás Z; MacAleenan N; Galli MC; Linē A; Gulbinovic J; Berchem G; Fraczek M; Menezes-Ferreira M; Vilceanu N; Hrubisko M; Marinko P; Timón M; Cheng W; Crosbie GA; Meade N; di Paola ML; VandenDriessche T; Ljungman P; D'Apote L; Oliver-Diaz O; Büttel I; Celis P
    Nat Rev Drug Discov; 2010 Mar; 9(3):195-201. PubMed ID: 20190786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comprehensive assessment of ATMP. Difficulties and approaches].
    Thanner M; Nagel E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):843-8. PubMed ID: 21698538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Medicines Agency, CAT Secretariat & US Food and Drug Administration.
    Regen Med; 2011 Nov; 6(6 Suppl):90-6. PubMed ID: 21999268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical trials with advanced therapy medicinal products].
    Schüssler-Lenz M; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Kočí Z; Boráň T; Krůpa P; Kubinová Š
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regulatory framework of innovative therapies : From bench to bedside].
    Walter C; Rohde B; Wicke DC; Pohler C; Lührmann A; von der Leyen H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):803-10. PubMed ID: 21698532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
    Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
    Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Scientific advice by the national and European approval authorities concerning advanced therapy medicinal products].
    Jost N; Schüssler-Lenz M; Ziegele B; Reinhardt J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1207-14. PubMed ID: 26369763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
    Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
    Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
    Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
    Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Classification of cell-based medicinal products and legal implications: An overview and an update].
    Scherer J; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014.
    Celis P; Ferry N; Hystad M; Schüßler-Lenz M; Doevendans PA; Flory E; Beuneu C; Reischl I; Salmikangas P
    Transfus Med Hemother; 2015 May; 42(3):194-9. PubMed ID: 26195933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.